T1	Participants 80 104	relapsed Hodgkin disease
T2	Participants 247 285	relapsed or refractory Hodgkin disease
T3	Participants 356 383	A tertiary referral center.
T4	Participants 393 524	Twenty-four patients (twelve of whom were controls) treated with high-dose chemotherapy and autologous bone marrow transplantation.
T5	Participants 1794 1868	patients with relapsed Hodgkin disease who received intensive chemotherapy
